Conditions: Breast Cancer
Keywords: Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 141
Healthy volunteers: no

Brief summary:
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.

Detailed description:

Arms:
arm 1: Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle

Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle arm 2: Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle

Interventions: intervention 1: Ramucirumab (IMC-1121B) intervention 2: Eribulin
Intervention descriptions: intervention 1: Administered intravenously intervention 2: Administered intravenously

Protocol document: